Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 5/20 | 0.34 |
| ▸ | GSK3B | P49841 | 5/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.34 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.34 |
| ▸ | CSNK1G1 | Q9HCP0 | 2/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | INSR | P06213 | 2/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24259069 | 0.88 | NR1H4 (0.42) | NR1H4USP7NPC1RAB9A | |
| SCHEMBL22353500 | 0.82 | NR1H4 (0.35) | KDRNR1H4GSK3AGSK3BFGFR2 | |
| SCHEMBL22353820 | 0.78 | NR1I2 (0.35) | KDRNR1H4GSK3AGSK3BFGFR2 | |
| SCHEMBL24259059 | 0.78 | NR1H4 (0.36) | KDRNR1H4CNR2NPC1RAB9A | |
| SCHEMBL24452269 | 0.77 | KCNT1 (0.35) | NR1H4NPC1RAB9A | |
| SCHEMBL22353498 | 0.76 | NR1H4 (0.53) | NR1H4 | |
| SCHEMBL24452241 | 0.75 | KCNT1 (0.35) | KDRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22354002 | 0.75 | NR1H4 (0.46) | NR1H4 | |
| SCHEMBL24258962 | 0.74 | NR1H4 (0.41) | NR1H4 | |
| SCHEMBL22354095 | 0.73 | DRD4 (0.44) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | KDR 3069/4885NR1H4 2/4885GSK3A 200/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | KDR 3069/4885NR1H4 2/4885GSK3A 200/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | KDR 3069/4885NR1H4 2/4885GSK3A 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.